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Abstract
Basal-like breast cancers (BLBCs) exhibit hyperactivation of the phosphoinositide 3-kinase (PI3K) 
signaling pathway because of the frequent mutational activation of the PIK3CA catalytic subunit 
and the genetic loss of its negative regulators PTEN (phosphatase and tensin homolog) and 
INPP4B (inositol polyphosphate-4-phosphatase type II). However, PI3K inhibitors have had 
limited clinical efficacy in BLBC management because of compensatory amplification of PI3K 
downstream signaling loops. Therefore, identification of critical PI3K mediators is paramount to 
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the development of effective BLBC therapeutics. Using transcriptomic analysis of activated 
PIK3CA–expressing BLBC cells, we identified the gene encoding the humoral pattern recognition 
molecule pentraxin-3 (PTX3) as a critical target of oncogenic PI3K signaling. We found that 
PTX3 abundance is stimulated, in part, through AKT- and nuclear factor κB (NF-κB)–dependent 
pathways and that presence of PTX3 is necessary for PI3K-induced stem cell–like traits. We 
further showed that PTX3 expression is greater in tumor samples from patients with BLBC and 
that it is prognostic of poor patient survival. Our results thus reveal PTX3 as a newly identified 
PI3K-regulated biomarker and a potential therapeutic target in BLBC.
INTRODUCTION
Basal-like breast cancer (BLBC) comprises a heterogeneous group of tumors that 
collectively account for ~15% of all breast cancers (1). They are more common in younger 
women, particularly of African-American descent (2, 3), and typically present with 
undifferentiated triple-negative breast cancer (TNBC) histological features and aggressive 
clinical behavior (4–6). BLBCs are, in their majority, unresponsive to current treatment 
regimens (7, 8), and refractory patients experience dismal outcomes with increased rates of 
recurrence within 1 to 3 years and heightened mortality rates within 5 years (5). Effective 
and targeted therapeutic approaches for BLBCs are therefore critically needed but remain to 
be defined.
At the molecular level, BLBCs display marked deregulations in a number of tumor 
suppressor pathways, such as p53, pRb, and BRCA1 (1). They also exhibit prominent 
activation of phosphoinositide 3-kinase (PI3K)–AKT signaling, a phenotype that is due, in 
part, to frequent loss of the PI3K pathway antagonists phosphatase and tensin homolog 
(PTEN) and inositol polyphosphate-4-phosphatase type II (INPP4B) (9). However, 
antagonizing PI3K activity in the context of BLBC clinical management is hampered by the 
emergence of resistance to a variety of PI3K inhibitors (10). Such resistance mechanisms do 
not seem to originate from the acquisition of secondary mutations in PI3K but, rather, by a 
series of compensatory mechanisms that amplify signal transduction pathways downstream 
of PI3K (11, 12). Therefore, identifying and inhibiting critical mediators of PI3K oncogenic 
activity would aid in the development of new and effective therapies targeting BLBC.
Here, we set out to identify previously unknown downstream effectors of PI3K in BLBC 
cells by conducting differential whole-genome transcriptomic analyses of basal-like 
MCF10A cells expressing an activated mutant of the catalytic subunit of PI3K 
(PIK3CAH1047R), a recurrent and frequent mutation observed in all molecular subtypes of 
breast cancer. We identified the inflammatory protein pentraxin-3 (PTX3) as a mediator of 
PI3K signaling and found that its presence is both necessary and sufficient for the 
acquisition of stem cell–like growth traits in BLBC cells. Our results revealed new functions 
for PTX3 as a PI3K-regulated biomarker, a supporter of stem-like phenotypes in breast 
cancer cells (BCCs), and a potential therapeutic target in BLBC.
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RESULTS
PI3K activation induces PTX3 expression in BLBC cells through AKT- and nuclear factor 
κB–dependent signaling
Comparative gene expression–based analysis of PIK3CAH1047R and wild-type (13) 
MCF10A cells revealed a significant [>1.5-fold; false discovery rate (FDR), 0] induction of 
231 genes in PIK3CAH1047R-expressing cells, which clustered into multiple gene sets using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) gene set 
enrichment analysis software (fig. S1A) (14). Twenty-one of the 231 induced genes 
belonged to the inflammatory response gene set (enrichment score, 11.13; P = 3.4 × 10−10), 
with the top hit being the inflammatory mediator PTX3, induced by PIK3CAH1047R ~3.9-
fold compared to wild-type cells (Fig. 1A and fig. S1B). PTX3 is a member of the pattern 
recognition molecule family of proteins and is expressed in a variety of cell types, 
particularly in hematopoietic and stromal cells responding to inflammatory signals such as 
interleukin-1β, tumor necrosis factor–α, or Toll-like receptor agonists (15). It is an acute 
phase protein that exerts pleiotropic protective functions in innate immunity, which include 
associating with microbial moieties, binding to certain microorganisms, facilitating pathogen 
recognition, activating complement cascades, and exhibiting opsonic activities (16). PTX3 
also exerts critical roles in the clearance of apoptotic cells, in leukocyte recruitment into 
inflamed tissues (17), and in matrix deposition during normal (such as oocyte cumulus) (18, 
19) or pathogenic matrix remodeling, such as after tissue injury (20, 21). This evidence 
suggests a central role for PTX3 in regulating both local and systemic inflammation. 
Whether PTX3 serves any role in BLBC, however, has not been determined.
PTX3 induction by PIK3CAH1047R expression was validated by RNA (Fig. 1B) and protein 
(Fig. 1C) determination, which revealed several-fold enrichment of each in PIK3CAH1047R 
cells. Conversely, inhibition of PI3K signaling by the pan-PI3K inhibitor BKM120 in 
PIK3CAH1047R-expressing MCF10A cells (Fig. 1C), by PIK3CA-specific short hairpin 
RNAs (shRNAs) in SUM159 cells (which harbor an endogenous H1047L-activated allele of 
PIK3CA) (Fig. 1D), or by the PI3K inhibitors BEZ235, BYL719, and BKM120 in SUM159 
and MDA-MB-231 cells (Fig. 1, E and F) inhibited both induced and basal PTX3 abundance 
suggesting that the PI3K pathway is critical to PTX3 expression. Furthermore, increased 
PTX3 expression correlated with PI3K pathway activation both in mouse models (Fig. 1G) 
and in clinical specimens (Fig. 1H). Notably, PTX3 expression correlated negatively with 
that of PTEN and INPP4B in breast tumors (Fig. 1H), further indicating that PTX3 may be 
regulated by activated PI3K signaling in multiple contexts.
We next investigated how PI3K might regulate PTX3 expression. Treating serum-starved 
SUM159 cells with MKK2206, a specific allosteric AKT inhibitor, suppressed endogenous 
PTX3 protein abundance (Fig. 1I), suggesting that AKT activation promotes PTX3 
abundance in PIK3CAH1047R -driven SUM159 cells. However, the fact that residual PTX3 
remained afterMKK2206 treatment suggested that PTX3 is likely regulated by additional 
AKT-independent pathways as well.
AKT stimulates the phosphorylation of Ser176 and Ser180 of IKKα [inhibitor of nuclear 
factor κB (NF-κB) (IκB) kinase α] and Ser177 and Ser181 of IKKβ, which in turn causes the 
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degradation of IκB (through phosphorylation at Ser32 and Ser36), while also activating p65 
by phosphorylating it at Ser536 (22). In light of this connection and the fact that the proximal 
promoter of PTX3 contains two strong NF-κB consensus sites (fig. S2C), we analyzed NF-
κB involvement in PI3K regulation of PTX3 expression. As predicted, PIK3CAH1047R 
stimulated NF-κB activation in MCF10A cells as revealed by the phosphorylation of IKKα/
β Ser176/180, IκB Ser32/36, and p65 Ser536, along with down-regulation of total IκB 
abundance when compared to controls (Fig. 1J). Treatment of these cells with the IKKβ 
adenosine 5′-triphosphate (ATP)–competitive inhibitor compound A, which inhibits the 
phosphorylation of IκB and p65, almost completely diminished PIK3CAH1047R-induced 
PTX3 abundance (Fig. 1J). These results were also observed in SUM159 cells, in which 
compound A reduced the abundance of PTX3 mRNA and protein (fig. S2, D and E). 
Together, these observations suggested that PTX3 is regulated in part by AKT- and NF-κB–
dependent signaling pathways.
PTX3 expression is specifically associated with BLBC cells
We next explored the involvement of PTX3 in breast cancer pathogenesis by examining the 
expression of PTX3 across publicly available clinical breast cancer gene expression data sets 
derived from the four major molecular subtypes of breast cancer: BLBC, human epidermal 
growth factor receptor 2 (HER2)–enriched, luminal A (LumA), and LumB. We found that 
PTX3 abundance was enriched (two- to seven-fold) in BLBC when compared to HER2, 
LumA, or LumB subgroups in a number of studies that included GSE1561 (23), GSE1456 
(24), TCGA (9), and UNC337 (Fig. 2, A to D) (25). The preponderance of PTX3 in BLBC 
was also observed in our own profiled breast cancer specimens collected at the Curie 
Institute (Fig. 2E) and was generalized to BLBCs compared to all non-BLBCs grouped 
together in the Dana-Farber Cancer Institute GSE7904 cohort (Fig. 2F) (26). Together, these 
observations indicated that PTX3 is particularly and abundantly expressed in BLBC.
PTX3 expression described above was derived from minced tumor tissues, which contain 
both cancer cells and their associated stroma. BLBCs are distinguished from other breast 
cancer subtypes by exhibiting high levels of immune cell infiltrates that can express PTX3 
(1, 15). To investigate whether cancer cells in clinical BLBC specimens expressed PTX3 per 
se, we dissected cancer cells from representative slides of the respective breast cancer 
subtypes and assessed PTX3 expression in the harvested RNA using qRT-PCR. In keeping 
with our genomic-based observations, BLBC cancer cells exhibited multifold enrichment of 
PTX3 compared to reduction mammoplasty–derived control tissues (Fig. 2G), whereas 
cancer cells derived from HER2, LumA, and LumB tumors displayed a 6- to 20-fold 
decrease in PTX3 expression when compared to controls or BLBC cells (Fig. 2G). Similar 
to MCF10A cells expressing PIK3CAH1047R, BCC lines associated with BLBC displayed, 
on average, >13-fold enrichment in PTX3 mRNA when compared to non-BLBC cancer 
cells, such as ZR75, MCF7, SKBR, or T47D cells (Fig. 2H), underscoring the tight 
association between PTX3 and BLBC.
We also evaluated the extent to which these observations can be generalized to multiple 
different BCC lines. For this purpose, we used the Broad Institute Cancer Cell Line 
Encyclopedia (CCLE) to identify a “PTX3 signature” that we then used to probe cell lines of 
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interest. We identified 19 genes that are mostly coexpressed with PTX3 across >260 cancer 
cell lines in the database (data file S1). We observed that this signature was enriched in 
BLBC cell lines, such as HCC1143, BT549, Hs578T, and MDA-MB-436, when compared to 
HER2 and luminal cell lines, such as HCC1954, MDA-MB-415, or BT474, which appear to 
be unanimously devoid of such expression patterns (Fig. 2I). These results confirm that 
PTX3 and its associated signature are highly and particularly enriched in BLBC.
PTX3 promotes cancer stem cell–like traits
The tight association of the PTX3 signature with BLBC prompted us to investigate whether 
PTX3 is further confined into a particular BLBC subset. As BLBCs are predominantly 
considered TNBCs because they mostly lack estrogen receptor and progesterone receptor 
expression as well as ERBB2 (also known as HER2) overexpression and/or amplification 
(4), we examined the enrichment of PTX3 signature in the six molecular TNBC subclasses 
proposed by Lehmann et al. (27): basal-like 1 (BL1), BL2, immunomodulatory (IM), 
mesenchymal (M), mesenchymal stem cell–like (M/MSL), and luminal androgen receptor 
(LAR)–positive tumors. These analyses revealed that PTX3 and its associated genes 
clustered more evidently with the M/MSL cells (six of six cell lines), whereas BL1/BL2 cell 
lines showed moderate-to-low expression, followed by the IM and LAR counterparts, which 
displayed depleted expression (Fig. 3A). Immunoblot analysis of the lysates of some of the 
lines presented in Fig. 3A also revealed preferential expression of the PTX3 protein in the 
M/MSL group (three of four cell lines) when compared to BL1, BL2, and LAR cells (one of 
seven cell lines; Fig. 3B). Moreover, increased PTX3 expression was observed in M/MSL 
patient-derived xenograft (PDX) models of breast cancer (M/MSL > BL1/2 ⋙ LAR/IM; Fig. 
3C), further supporting a link between PTX3 expression and the M/MSL group.
The M and MSL subtypes are enriched for genes/pathways that regulate, among others, 
cellular motility, extracellular matrix interactions, and cellular differentiation and are 
reminiscent of the intrinsic claudin-low (CL) phenotype, as previously characterized (25). 
M/MSL/CL subtypes share common features that include enrichment in genes encoding the 
proteins that regulate epithelial-to-mesenchymal transition (EMT; such as SNAIL and 
TWIST), low expression of tight junction proteins (such as claudins 3, 4, and 7), and 
increased abundance of genes encoding proteins associated with cancer stem cells (CSCs; 
such as ALDHA1 and HOX). When BCC lines were aligned according to the CL 
classification, we noticed a robust up-regulation of the PTX3 gene signature in six of seven 
queried cell lines (Fig. 3D). Moreover, although PTX3 abundance was increased in cells 
such as Hs578T, SUM159, or MDA-MB-231, which also cluster with CL cells (25), we 
found detectable PTX3 abundance in HCC1143 and HCC38 cells, as well as high abundance 
in SUM149 cells (Fig. 3B), and BL1/2 cell lines contained significant numbers of CL cells 
within them (25). We further tested the association of PTX3 with the CL phenotype by 
probing human mammary epithelial (HMLE) cells that exogenously express the embryonic 
transcription factors goosecoid (GSC), SNAIL, and TWIST, variants that segregate along the 
CL subtype (28). Here too, PTX3 expression was induced 5- to 15-fold (Fig. 3E). Finally, 
CL clinical samples extracted from UNC337 exhibited comparable enrichment in PTX3 
versus their BLBC counterparts (Fig. 3F). Together, these findings support a strong 
association between PTX3 and the M, MSL, and CL breast cancer subtypes.
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As discussed above, the M, MSL, and CL subtypes are characterized by overrepresentation 
of genes associated with EMT and CSC regulation, and M/MSL/CL tumors have such 
features (25, 27). In addition, the PTX3-associated gene expression signature revealed genes 
implicated in stem cell and/or EMT state regulation in BLBC, such as LOX (29), LOXL2 
(30), COL6A1/2 (31), AXL (32), VEGFC (33), and SPARC (34). We therefore evaluated 
whether PTX3 regulated EMT or CSC traits in basal-like mammary epithelial cells. We 
found that stable over-expression of PTX3 from a pBabe retroviral construct in MCF10A 
cells did not cause significant down-regulation of epithelial markers (such as zonula 
occludens-1 or E-cadherin) (fig. S3A), did not promote up-regulation of mesenchymal 
markers (such as fibronectin, smooth muscle actin, or vimentin) (fig. S3B), and did not 
cause any detectable morphological changes in the cells relative to control counterparts (fig. 
S3C), indicating that PTX3 alone is not sufficient in triggering EMT in these contexts. In 
contrast, PTX3-overexpressing MCF10A cells were able to form twice as many 
tumorspheres in suspension compared to control cells (Fig. 4A), exhibited significant 
enrichment (16%) in their CD44hi/CD24low/neg CSC-like populations (Fig. 4B), and 
displayed a fourfold increase in their positivity for the CSC-associated marker aldehyde 
dehydrogenase 1 (ALDH1) (Fig. 4C) (35). Similar observations were made in MDA-
MB-231 and BT549 cells, where ectopic PTX3 expression enhanced primary and secondary 
tumorsphere formation and ALDH1 positivity (fig. S3, D and E). Furthermore, we found 
that inhibiting the expression of endogenous PTX3 in SUM159 cells using shRNAs 
(shPTX3) caused up to 40% inhibition in CD44hi/CD24low/neg (Fig. 4D) and almost 
abrogated ALDH1 positivity in SUM159 and MDA-MB-231 cells (Fig. 4D and fig. S3F). 
These observations suggested that PTX3 is involved in regulating CSC-like phenotypes in 
basal-like breast cells.
To assess the functional contributions of PTX3 to PI3K signaling, we inhibited PTX3 
expression using shRNAs in the background of PI3K activation. We and others have 
previously shown that PI3K signaling mediates cell proliferation under growth factor 
deprivation and that it strongly regulates stem cell traits in breast (and other) cancer cells 
(36–38). PIK3CAH1047R promoted a sevenfold increase in the number of ALDH1-positive 
cells (Fig. 4E), stimulated cell proliferation under EGF deprivation (Fig. 4F), and mediated 
tumorsphere growth (Fig. 4G). Conversely, shPTX3 inhibited all these phenotypes, 
abrogating PIK3CAH1047R-induced ALDH1 stimulation and inhibiting cancer cell growth in 
two- and three-dimensional culture assays (Fig. 4, E to G). Notably, PTX3 was a powerful 
prognostic indicator for worse overall survival (Fig. 4H) and worse relapse-free survival (Fg. 
4I) in the UNC337 cohort, which is enriched with M/MSL/CL specimens. Collectively, our 
results suggest a model in which PTX3 serves as an intrinsic mediator of PI3K-regulated 
CSC-like traits in BLBC cells.
DISCUSSION
When compared to other breast cancer subtypes, BLBCs exhibit the highest activation 
patterns in the PI3K/AKT pathway (9). This is due, in part, to the frequent loss of PTEN and 
INPP4B, as well as to a substantial frequency of activating mutations in PIK3CA. Therefore, 
identifying signaling effectors that are critical for PI3K/AKT functions in BLBC will 
provide important and relevant targets for BLBC therapy. On the basis of our findings, we 
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propose that PTX3 represents one such signaling effector. PI3K pathway activation induced 
PTX3 in cellular and mouse models of BLBC and positively associated with PTX3 
expression in clinical settings. Furthermore, inhibition of PTX3 alone was sufficient to 
suppress PI3K-stimulated growth, strongly underscoring its functions as a critical mediator 
of oncogenic PI3K signaling. In support of this hypothesis are the observations that NF-κB 
was necessary to drive PTX3 expression and that PTX3, in turn, regulated the propagation of 
stem cell–like traits in cancer cells, phenotypes that are highly enriched in BLBC (39) and 
promoted by PI3K and NF-κB (38, 40–42). On the basis of these results, as well as the 
recognized role of CSC-like populations in driving BLBC malignancy (43), we speculate 
that PTX3 represents both a novel biomarker and a potential therapeutic target in BLBC.
How PTX3 regulates BCC growth and how it propagates CSC-like traits in BLBC cells 
remain to be determined. We found that PTX3 expressed by BLBC cells was soluble (fig. 
S3A), and therefore, it is possible that BCC-derived PTX3 acts in an autocrine/paracrine 
manner through its proper and yet-to-be-identified receptor(s) on the surface of cancer cells. 
In light of its reported activities as a rudimentary antibody (21), it is also plausible that 
PTX3 acts by cross-linking growth factor receptors residing at cell surfaces.
Correlative biomarker studies previously described increased in situ and/or systemic PTX3 
abundance in patients with lung (44, 45), prostate (46), ovarian (13), liver (47), and 
pancreatic (48) tumors, as well as in those with cancer-prone myeloproliferative diseases 
(49), suggesting that PTX3 serves as a cancer biomarker and potentially functions in cancer-
supportive roles similar to the ones described here. In breast cancer, Scimeca et al. (50) also 
correlated increased immunohistochemical PTX3 staining with poorly differentiated 
aggressive breast cancers and related stromal PTX3 production to increased chemotherapy 
resistance of BCCs (51). Although these collective findings are in support of the 
promalignant roles we describe for PTX3 in the present work, these observations are in 
sharp contrast to other studies in which PTX3 was found to exert suppressive roles in tumor 
pathogenesis.
However, the prevalent model for PTX3 involvement in tumor development depicts its 
paracrine activities as a microenvironmental factor that promotes tumor suppression. In this 
scheme, PTX3 was found to bind certain members of the fibroblast growth factor (FGF) 
family (in particular FGF2 and FGF8b), suppressing FGF-induced neovascularization and 
hampering tumor formation in xenograft models (52, 53). Similarly, PTX3 was shown to 
exert antimetastatic effects in melanoma (54) and to act as an extrinsic factor that inhibits 
cancer growth in a variety of additional heterotypic, syngeneic, and autochthonous prostate, 
lung, and pancreatic tumor models (55). These notions were further reinforced by Bonavita 
et al. (56), who showed that PTX3 ablation sensitized animals to carcinogen-induced 
tumorigenesis through the creation of a favorable immune tumor microenvironment that in 
turn stimulated oxidative stress and genetic instability in the cancer cells. These results 
underscore a role for PTX3 as a determining regulator of cancer-related inflammation (CRI), 
which exerts extrinsic activities in suppressing tumor initiation and development. Notably, 
the PTX3 gene was found to be highly methylated in human tumor cells, such as in 
esophageal cancers (57), leiomyosarcomas (56), and colorectal cancers (56, 58), suggesting 
a beneficial role for certain cancer cells to suppress their intrinsic production of PTX3. In 
Thomas et al. Page 7
Sci Signal. Author manuscript; available in PMC 2018 March 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
contrast, however, our results show that PTX3 is highly expressed in BLBC cells and that it 
acts as an intrinsic oncopromoter that is prognostic of worse survival outcomes in BLBCs 
(Fig. 1H), subtypes characterized by increased CRI (59) and heightened genetic instability 
(60). Collectively, our results support a model in which functions of PTX3 in cancer 
pathogenesis are likely to be context-dependent and that PTX3-targeting therapies need to be 
rationalized together with the type, genetic background, and composition of both cancer 
cells and their associated stroma.
MATERIALS AND METHODS
Gene expression analyses
Gene expression analysis of MCF10A cells stably expressing PIK3CAH1047R versus wild-
type PIK3CA were performed using a Human SurePrint G3 GE v2 platform (Agilent) as 
standard. Data were analyzed from triplicate runs and stratified with respect to statistical 
significance. Gene ontology was performed using the DAVID software (david-d.ncifcrf.gov) 
(14). Data are deposited in Gene Expression Omnibus (GSE93422).
Constructs
Human PTX3 amplified from human complementary DNA of normal prostatic tissues and 
verified by sequencing to be free of mutations was cloned into the pBabe-puromycin 
plasmid obtained from R. Weinberg. Expression constructs coding for wild-type and 
H1047R-mutant PIK3CA, pLP-LNCX-PIK3CA-WT (Addgene plasmid #25633), and pLP-
LNCX-PIK3CA-H1047R (Addgene plasmid #25635) were obtained from T. Waldman. 
shRNA constructs in the pLKO.1-puromycin lentiviral system raised against human PTX3 
were purchased from the RNAi Facility at the Dana-Farber Cancer Institute. For shRNAs 
against PIK3CA, single-stranded sense and antisense oligonucleotide pairs PIK3CA 
shRNA#1 (sense, 5′-
CCGGGCACAATCCATGAACAGCATTCTCGAGAATGCTGTTCATGGATTGTGCTTTT
TTG-3′), PIK3CA shRNA#1 (antisense, 5′-
AATTCAAAAACACAATCCATGAACAGCATTCTCGAGAATGCTGTTCATGGATTGTG
-3′), PIK3CA shRNA#2 (sense, 5′-
CCGGGCATTAGAATTTACAGCAAGACTCGAGTCTTGCTGTAAATTCTAATGCTTTT
TTG-3′), and PIK3CA shRNA#2 (antisense, 5′-
AATTCAAAAAGCATTAGAATTTACAGCAAGACTCGAGTCTTGCTGTAAATTCTAAT
GC-3′) were synthesized and cloned into pLKO.1 vector. Lentiviral supernatants were 
collected after 48 hours from 293T cells cotransfected with the respective pLKO-shRNA 
constructs, VSVG and psPAX2, and used to infect target cells in the presence of polybrene. 
Cells stably expressing the respective shRNAs were selected and cultured in growth medium 
containing puromycin (2 µg/ml).
BCC lines
BCC lines MDA-MB-468, HCC1937, HCC1143, SUM149, BT549, Hs578T, SUM159, 
MDA-MB-231, HCC70, HCC38, ZR75, MCF7, SKBR, and T47D were purchased from the 
American Type Culture Collection (ATCC) and propagated according to the conditions 
specified by ATCC. MCF10A cells were obtained from J. Brugge (Harvard Medical School) 
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and were cultured in Dulbecco’s modified Eagle’s medium/Ham’s F12 medium 
supplemented with 5% equine serum (Gibco BRL), insulin (10 µg/ml), hydrocortisone (500 
ng/ml) (Sigma-Aldrich), EGF (20 ng/ml) (R&D Systems), and cholera toxin (100 ng/ml) 
(List Biological Laboratories). HMLE cells expressing GSC, SNAIL, and TWIST were 
obtained from R. Weinberg.
Pathway inhibitors
Inhibitors BKM120 (#A-1108), BEZ235 (#A-1009), BYL719 (#A-1214), and MKK2206 
(#A-1206) were purchased from Active Biochem Co. The IKKβ ATP–competitive inhibitor 
compound A (61) was manufactured by Bayer Pharmaceuticals.
Western blot analyses
Cell lysates were prepared using radioimmunoprecipitation assay buffer in the presence of 
protease and phosphatase inhibitors, and cleared proteins were resolved by gel 
electrophoresis, transferred by electrophoresis to nitrocellulose membranes, and processed 
for Western blotting as is standard using the following antibodies: antibody against PTX3 
was purchased from LSBio (#LS-C138995); antibodies against p110α (#4249), 
phosphorylated (phospho)–AKT Ser473 (#4060), phospho-AKT Thr308 (#2965), AKT 
(#4691), phospho-PRAS40 Thr246 (#2997), PRAS40 (#2691), phospho-GSK3β Ser9 
(#9336), GSK3β (#9315S), phospho-p70S6K (#9204), S6P (91B2; #4857), Z0-1 (#5406 and 
#5406), E-cadherin (4A2, #14472), β-tubulin (#2128), N-cadherin (#4061), vimentin 
(#5741), p85 (#4292), β-actin (#4970), IKKα/β Ser176/180 (#2697), phospho-IκBα Ser32/36 
(#9246), IκBα (#9247), phospho–NF-κBp65 Ser536 (#3033), and NF-κB p65 (#8242) were 
purchased from Cell Signaling Technology. Antibodies raised against fibronectin and 
smooth muscle actin were purchased from BD Transduction (#610078) and Abcam 
(ab5694), respectively. Blots were developed using horseradish peroxidase–conjugated 
secondary antibodies using chemoluminescence (Millipore and Chemicon).
qRT-PCR analysis
PTX3 mRNA expression was determined by qRT-PCR on total cellular RNA extracted using 
the RNeasy protocol (Qiagen). RNA was reverse-transcribed using QuantiTect Reverse 
Transcription Kit (Qiagen), and the product was amplified using SYBR Green PCR Master 
Mix (Bio-Rad) in an ABI Prism 7900 sequence detector (Applied Biosystems). PTX3 
mRNA abundance was determined using the ΔΔCt method and normalized to GAPDH or 
18S. Primers used were as follows: PTX3 forward, 5′-GCTCTCTGGTCTGCAGTGTT-3′ 
or 5′-CATCCAGTGAGACCAATGAG-3′; PTX3 reverse, 5′-
CTTGTCCCATTCCGAGTGCT-3′ or 5′-GTAGCCGCCAGTTCACCATT-3′; 18S forward, 
5′-GTAACCCGTTGAACCCCATT-3′; 18S reverse, 5′-
CCATCCAATCGGTAGTAGCG-3′; GAPDH forward, 5′-
GCAAATTCCATGGCACCGT-3′; and GAPDH reverse, 5′-
TCGCCCCACTTGATTTTGGAGG-3′.
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Clinical analyses
PTX3 determinations in GSE1561 (23) were derived from the ROCK Breast Cancer 
Functional Genomics database (62). PTX3 expression from breast cancer data sets in 
GSE1456 (24), TCGA (9), UNC337 (25), and GSE7904 (26) was derived from retrieved raw 
data of the original studies, which were log2-transformed and normalized at the gene level 
using the original normalization provided by the respective authors or using the frozen 
robust multiarray analysis algorithm. For survival analysis, median-centered log ratios from 
UNC337 were partitioned into groups of high, medium, or low PTX3 expression by 
comparing the median of all samples. Survival analysis was performed using Kaplan-Meier 
estimates using the log-rank test and the proportional hazard model to compare survival 
curves. For biospecimen analysis (in Fig. 2G), total RNA was extracted from cancer cell–
enriched (50 to 80% tumor) macrodissected tumors using RNeasy (Qiagen) under approved 
Curie Institute institutional review board (IRB) protocols. Normal control tissue originated 
from normal tumor margins.
CCLE-derived PTX3 coexpressed genes
The expression of PTX3 and its 19 closest coexpressed genes were determined on the 
indicated BCC lines using CCLE. CCLE provides public access to genomic data of multiple 
cancer cell lines available for analysis and visualization at www.broadinstitute.org/ccle.
Patient-derived cancer xenografts
PDX models of breast cancer were established at the Curie Institute (Paris, France), as 
previously published (63) under approved IRB and Institutional Animal Care and Use 
Committee protocols. Subtyping of TNBC PDX models was done on the basis of the 
published signature of Lehmann et al. (27) and Chen et al. (64).
Tumorsphere assays
Sphere-forming abilities of BCCs were conducted as previously described (29). Briefly, 
BCCs were seeded at 1000 cells per well in ultralow-attachment six-well plates for 5 days. 
Suspensions were then flushed, and >70-µm colonies were counted under a microscope. For 
secondary and tertiary sphere–forming activities, the primary or secondary spheres, 
respectively, were dissociated with Trypsin, counted, and reseeded at a density of 1000 cells 
per well for another 5 days.
FACS analyses
Cell lines were suspended, labeled with FITC-conjugated antibody against CD44 and PE-
conjugated antibody against CD24, and processed for FACS analyses as is standard. For 
ALDH assays, cells were suspended in ALDEFLUOR assay buffer (STEMCELL) with 
ALDH1 substrate for 1 hour at 37°C and analyzed using the FITC channel. The ALDH 
inhibitor DEAB served as a negative control for specific ALDEFLUOR staining. FACS was 
conducted using the FACSCanto System (BD Biosciences).
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Sulforhodamine B assay
Cell viability was assessed using sulforhodamine B (SRB) assay as previously described 
(65). Briefly, adherent cells were fixed with trichloroacetic acid for 1 hour at 4°C and then 
rinsed and stained with SRB in 1% acetic acid for at least 30 min at room temperature. Cells 
were then washed and allowed to dry, and solubilized SRB was measured at 510 nm.
Statistical analysis
All experiments were repeated two or three times. Results were expressed as means ± SEM. 
Data were analyzed using a two-sided Student’s t test or one-way ANOVA after confirming 
their normal distribution. The log-rank test was used to analyze data in survival experiments. 
P < 0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. PI3K activation triggers PTX3 expression in BLBC cells
(A) Fold induction of the top 10 genes up-regulated by PIK3CAH1047R (HR) expression in 
MCF10A cells relative to wild-type (WT) PIK3CA expression. (B) Quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) measurements of PTX3 mRNA 
abundance in MCF10A cells stably expressing WT (13) or HR. Data are means ± SEM of n 
= 3 independent experiments, each performed in triplicate. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase. (C) Representative Western blot analysis of MCF10A cells stably 
expressing WT or HR treated with BKM120 (1 µM for 24 hours) (+) or vehicle control (−) 
and deprived of epidermal growth factor (EGF) and insulin (n > 3). (D) Top: Representative 
Western blot of SUM159 cells stably expressing control (CTRL) or PIK3CA shRNAs. 
Bottom: qRT-PCR measurements of PTX3 mRNA normalized to GAPDH in the indicated 
SUM159 variants. Data are means ± SEM of n = 3 independent experiments, each 
performed in triplicate. (E) Representative Western blot analysis of SUM159 cells treated 
with vehicle (−), BEZ235 (5 µM), BKM120 (1 µM), or BYL719 (1 µM) for 24 hours (n > 3). 
(F) Representative Western blot analysis of MDA-MB-231 cells treated with vehicle (−) or 
with BEZ235 (5 µM) for 24 hours (n > 3). (G) PTX3 transcript abundance derived from 
microarrays of mouse tumors (GSE41118) driven by HER2 (n = 6), HR (n = 6), or HER2 + 
HR (n = 7). (H) Spearman’s and Pearson’s correlation analyses of PTX3 expression with 
that of activated PIK3CA gene signature derived from Hutti et al. (36), PTEN BIOCARTA 
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pathway, and INPP4B gene in the UNC337, The Cancer Genome Atlas (TCGA), and in 
GSE5460 (66) databases, respectively. (I) Representative Western blot analysis of SUM159 
cells treated with vehicle (−) or MK2206 (1 µM) for 24 hours (n > 3). (J) Representative 
Western blot analysis of control or HR MCF10A cells treated with compound A (Cmpd A; 5 
µM) for 24 hours (n > 3). *P < 0.05 and **P < 0.01, by unpaired t test. Exp., exposure.
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Fig. 2. PTX3 expression is specifically associated with BLBCs
(A) PTX3 expression (probe 206157_at) in GSE1561 analyzed using significance analysis 
of microarrays (SAMs) in ROCK Breast Cancer Functional Genomics database: BLBC (n = 
15), HER2 (n = 8), and LumB (n = 23); FDR, 0%. (B) PTX3 expression (probe 206157_at) 
in GSE1456 analyzed by SAMs: BLBC (n = 25), HER2 (n = 15), LumA (n = 39), LumB (n 
= 23); FDR, 0%. (C) Analysis of variance (ANOVA) box plot analyses for PTX3 (probe 
206157_at) in TCGA; P = 5.63 × 10−50. (D) ANOVA box plot analyses for PTX3 (probe 
206157_at) in UNC337; P = 2.97 × 10−32. (E) ANOVA box plot analysis of PTX3 (probe 
206157_at) in breast cancer samples collected at the Curie Institute: BLBC (n = 78),HER2 
(n = 31), LumA (n = 28), and LumB (n = 32); P = 4.89 × 10−25. (F) ANOVA box plot 
analysis of PTX3 (probe 206157_at) in GSE7904; BLBC (n = 18) and non-BLBC (n = 21); 
P = 1.723 × 10−9. (G) qRT-PCR analysis of PTX3 expression in RNA from dissected BCCs 
lifted off slides of the indicated tumor samples: Control (n = 5), BLBC (n = 16), HER2 (n = 
13), LumA (n = 25), LumB (n = 22). *P < 0.05 and **P < 0.01, by unpaired t test. (H) qRT-
PCR measurements (means ± SEM of n > 3) of PTX3 mRNA abundance in the indicated 
BCC lines. Values were normalized to that of 18S and are displayed as arbitrary units 
(A.U.). (I) PTX3 and 19 most closely associated genes across all the cancer cells represented 
in the Broad Institute CCLE (called here “PTX3 gene signature”) were profiled in the 
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indicated BCC lines, grouped according to breast tumor subtype. Red and blue indicate 
increased and diminished expression of PTX3, respectively.
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Fig. 3. PTX3 is particularly enriched in M/MSL/CL BCCs
(A) PTX3 gene expression signature in the indicated BLBC subclasses from Lehmann et al. 
(27). (B) Representative Western blot on PTX3 in the indicated BCC lines (n > 3). (C) 
ANOVA box plot of PTX3 expression (NM_00282) in PDX models of indicated breast 
cancer subtypes. BL1/2 (n = 13), LAR (n = 2), M/MSL (n = 11), IM (n = 1); P = 0.008. (D) 
PTX3 gene signature across the indicated BCC lines, grouped according to molecular 
classification (25). (E) qRT-PCR analyses of PTX3 mRNA in HMLE cells stably expressing 
the transcription factors GSC, SNAIL, and TWIST, relative to that in controls. Data are 
means ± SEM of triplicates from ≥3 independent experiments. *P < 0.05 and **P < 0.01, by 
unpaired t test. (F) ANOVA box plot analyses for PTX3 expression (probe 206157_at) in 
BLBC and CL subtypes from the UNC337 database; P = 1.07 × 10−4.
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Fig. 4. PTX3 is a critical and functional effector of PI3K signaling
(A) Controls or PTX3-expressing MCF10A cells were plated in triplicates in low-adherence 
plates and scored for their ability to form tumorspheres after the indicated serial passages. 
Data are means ± SEM of triplicates from ≥3 independent experiments. (B and C) Controls 
or stable PTX3-expressing MCF10A cells were analyzed for their expression of CD44 
[fluorescein isothiocyanate (FITC)] and CD24 [phycoerythrin (PE)] (B) or ALDH positivity 
(C) (red gate) using FACS (fluorescence-activated cell sorting). Data are representative of 
more than three experiments. (D) qRT-PCR measurements of PTX3 mRNA abundance in 
SUM159 cells stably expressing control or PTX3-specific shRNA molecules. Variants 
expressing the indicated shRNA were analyzed for their ALDH positivity and CD44/CD24 
expression using FACS. Data are means ± SEM in triplicates of more than three independent 
experiments. (E) ALDH positivity of controls or MCF10A cells harboring control shRNA 
(shctrl) or shPTX3 constructs in the WT or HR backgrounds. Data are means ± SEM from 
≥3 experiments. (F) Representative images of sulforhodamine-stained, 4-day cultured 
MCF10A cells stably expressing HR or controls, along with shctrl or shPTX3. Viable cell 
count was determined colorimetrically. Data are means ± SEM of three independent 
biological replicates, each performed in triplicate. (G) Control or shPTX3-expressing 
MCF10A cells harboring control or HR expression vectors were plated in triplicates in low-
adherence plates and scored for their ability to form tumorspheres at first passage. Data are 
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means ± SEM of triplicates from ≥3 independent experiments. (H and I) Kaplan-Meier 
analysis of overall survival (H) and relapse-free survival (I) in UNC337 estimated on patient 
cohorts whose breast tumors harbored low, medium, and high PTX3 expression. (H) P = 
0.00907 and (I) P = 0.00748, calculated by log-rank test. (A, C, D, E, and G) *P < 0.05, **P 
< 0.01, and ***P < 0.001, by unpaired t test. SSC, side scatter.
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